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In this review article we discuss current knowledge about iron in the skin and the cutaneous
wound healing process. Iron plays a key role in both oxidative stress and photo-induced
skin damage. The main causes of oxidative stress in the skin include reactive oxygen
species (ROS) generated in the skin by ultraviolet (UVA) 320–400 nm portion of the UVA
spectrum and biologically available iron. We also discuss the relationships between iron
deﬁciency, anemia and cutaneous wound healing. Studies looking at this fall into two
distinct groups. Early studies investigated the effect of anemia on wound healing using a
variety of experimental methodology to establish anemia or iron deﬁciency and focused
on wound-strength rather than effect on macroscopic healing or re-epithelialization. More
recent animal studies have investigated novel treatments aimed at correcting the effects
of systemic iron deﬁciency and localized iron overload. Iron overload is associated with
local cutaneous iron deposition, which has numerous deleterious effects in chronic venous
disease and hereditary hemochromatosis. Iron plays a key role in chronic ulceration and
conditions such as rheumatoid arthritis (RA) and Lupus Erythematosus are associated with
both anemia of chronic disease and dysregulation of local cutaneous iron hemostasis. Iron
is a potential therapeutic target in the skin by application of topical iron chelators and novel
pharmacological agents, and in delayed cutaneous wound healing by treatment of iron
deﬁciency or underlying systemic inﬂammation.
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INTRODUCTION
Iron is a vital co-factor for proteins and enzymes involved in energy
metabolism, respiration,DNAsynthesis, cell cycle arrest and apop-
tosis. Over the past 10 years, major advances have been made in
understanding the genetics of iron metabolism and this has led to
identiﬁcation of a number of new proteins, including hepcidin, an
acute phase protein that is the master regulator of iron absorption
and utilization, often activated in chronic diseases (Weiss, 2009;
Finberg, 2013).
Historically, it has long been known that iron is essential for
healthy skin, mucous membranes, hair and nails. Clinical features
of iron deﬁciency include skin pallor, pruritus, and predisposition
to skin infection (impetigo, boils and candidiasis), angular chelitis,
swollen tongue, fragile nails, kolionychia, and dry brittle hair.
ROLE OF IRON IN THE SKIN
NORMAL PHYSIOLOGY OF IRON
The normal physiology of iron in the skin is complex and not
clearly understood. It is known that iron levels in normal epider-
mis are thought to vary over awide range (Molin andWester, 1976;
Kurz et al., 1987). Within normal dermis, iron levels also vary and
are thought to increase during the aging process (Leveque et al.,
2003). Furthermore, iron-containing proteins have speciﬁc func-
tion such as the metabolism of collagen by procollagen-proline
dioxygenase (Richardson et al., 1996; Polefka et al., 2012; Figure 1).
Iron is not actively excreted from the body, however the skin
is a key organ in iron hemostasis as iron is lost through the
skin by desquamation (Figure 2). Current theories regarding the
underlying mechanisms of desquamation include active dissolu-
tion of desmosomes involved in keratinocyte cell–cell adhesion,
by hydrolytic protease digestion (Milstone, 2004). Desquamation
of keratinocytes is thought to account for 20–25% of absorbed
iron that is lost (Jacob et al., 1981). Yet overall, the daily loss of
iron by desquamation is approximately 25% that of daily urinary
iron excretion (Molin and Wester, 1976). Evidence is emerging
from genetic model mouse studies by Milstone et al. (2012) that
both loss of iron by desquamation and local changes in epider-
mal iron metabolism have some role in systemic iron metabolism
(these studies investigated three groups of mice: ﬁrstly mice over-
expressing of HPV16 E7 gene, which causes a threefold increase in
epidermal turnover, secondly mice overexpressing the transferrin
receptorwhich causes a three to fourfold increase of epidermal iron
in a skinmodel, and ﬁnally a systemic hemochromatosis knockout
model crossed with the epidermal iron sink model). Additionally,
gender-related differences in iron statusmay be responsible for the
increased longevity of women as compared to men. The relative
difference in cell iron levels between the sexes may be of impor-
tance both physiologically and in setting of pathophysiological
conditions (Pouillot and Polla, 2013).
IRON, OXIDATIVE STRESS, AND PHOTO-INDUCED DAMAGE
The main causes of oxidative stress in the skin are reac-
tive oxygen species (ROS) generated in the skin by ultravio-
let (UVA) 320–400 nm portion of the UVA spectrum. Iron
plays a key role in oxidative stress processes, as it is a tran-
sition metal, which exists in two stable states, Fe2+ (electron
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FIGURE 1 | Role of iron in the skin – an overview.
donor) and Fe3+ (electron acceptor). Intracellular labile iron can
undergo redox cycling between its most stable oxidation states
(Fe2+/Fe3+) and react with ROS such as superoxide anion, hydro-
gen peroxide, giving rise to hydroxyl radicals via the Fenton
reaction or superoxide-driven Fenton chemistry (Pelle et al.,
2011).
Exposure of skin ﬁbroblasts to UVA can generate ROS that pro-
mote oxidative damage in lysosomal,mitrochondrial, nuclear, and
plasmamembranes. Ultimately loss of plasmamembrane integrity
together with mitrochondial ATP depletion results in necrotic
cell death (Aroun et al., 2012). It is thought that compared with
skin ﬁbroblasts, keratinocytes are more resistant to UVAmediated
membrane damage and cytotoxicity. In vitro studies have shown
that although UVA starts lysosomal damage, ferritin degrada-
tion and cytosolic labile iron release in keratinocytes, the absolute
level of UVA induced labile iron release is several fold lower than
in ﬁbroblasts, suggesting a link between labile iron release and
keratinocyte resistance to UVA mediated damage (Zhong et al.,
2004).
ANEMIA, IRON DEFICIENCY, AND CUTANEOUS WOUND
HEALING
Wound healing is a dynamic and highly regulated process consist-
ing of cellular, humoral and molecular mechanisms (Reinke and
Sorg, 2012). The normal cutaneous wound healing process is a
temporal process involving a complex series of overlapping events,
which can be divided into key stages including: hemorrhage and
ﬁbrin-clot formation, inﬂammatory response, re-epithelialization,
granulation tissue formation, angiogenic response, connective
tissue contraction, and remodeling, see Figure 3.
FIGURE 2 | Normal physiology of iron homeostasis. Figure adapted to show key iron physiology including iron loss by desquamation (see Milstone et al.,
2012).
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FIGURE 3 |The temporal stages of cutaneous wound healing and key cell types involved. (A) Graph illustrating the key temporal stages of wound healing
over the 14 days post injury. (B)The key cell types involved in the wound healing process.
EXPERIMENTAL STUDIES – IRON, ANEMIA, AND WOUND
HEALING
In current literature, animal studies fall into two distinct groups.
Early studies investigating the effect of anemia on wound healing
used a variety of experimental methodology to establish ane-
mia or iron deﬁciency. They focused on wound strength studies
rather than initial macroscopic healing or histological studies of
re-epithelialization. More recent studies have investigated novel
treatments aimed at correcting the effect of systemic iron deﬁ-
ciency and topical application of iron-chelators to reduce iron at
the speciﬁc site of inﬂammation and in particular their effect on
pro inﬂammatory macrophages.
IN VIVO STUDIES – THE EFFECT OF IRON DEFICIENCY ON WOUND
HEALING
Early initial experimental rodent studies used powdered milk
diet to establish iron deﬁciency. Jacobson and Vanprohaska
(1965) found that chow-fed control mice showed signiﬁcantly
higher wound breaking-strength than anemic mice that were
fed on an iron-free powdered milk diet. Bains et al. (1966)
found that young rats fed low iron (powdered milk) diet and
subjected to repeated bleeding to produce chronic anemia had
weaker wound tensile strength. However, later studies under-
taken by Macon and Pories (1971) had contrary ﬁndings;
iron-deﬁciency anemia (IDA) had no effect on wound break-
ing strength. This may reﬂect the methodological issues when
using powdered milk to establish iron deﬁciency as Waterman
et al. (1952) showed that control and anemic rats fed pow-
dered milk had slower wound contraction and reduced wound
breaking strength, when compared with animals fed normal
chow.
Investigation into the impact of anemia and blood volume on
wound healing strength by Sandberg and Zederfeldt (1960) found
that replacing blood volume with dextran restored normal wound
healing, following acute hemorrhage in a rabbit model. Heughan
et al. (1974) found that there was no signiﬁcant change in wound-
ﬂuid oxygen tension (PO2) in rabbits made anemic by bleeding
and re-transfusing plasma. Additionally, connective tissue weight
was greater at lower packed cell volumes, an initial ﬁnding that
suggested a deleterious effect of hypoxia on collagen synthesis.
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Oliveira Sampaio et al. (2013) investigated the effect of deliv-
ery of an iron free diet for 15 days in Wistar rats, though
histological study of excisional wounds at 7, 14, and 21 days post-
healing. LED light caused a signiﬁcant positive bio-modulation
of ﬁbroblastic proliferation in anemic animals, with laser being
more effective on increasing proliferation in non-anemic ani-
mals. This study did not describe the effect of iron deﬁciency
on the early stages of wound healing (re-epithelialization) or later
resolution.
There are various mechanisms by which iron deﬁciency may
impair wound healing. Current evidence favors a key role played
by hypoxia. Hypoxia-inducible factor-1 (HIF-1) contributes to
all stages of wound healing (through its role in cell migration,
cell survival under hypoxic conditions, cell division, growth
factor release, and matrix synthesis) and positive regulators
of HIF-1, such as prolyl-4-hydroxylase inhibitors, have been
shown to be beneﬁcial in enhancing diabetic healing (Hong
et al., 2014). Further studies are required to directly answer this
question.
Of note, the functional role of iron in the wound healing
process has not undergone detailed in vitro study. Recent inter-
est in lactoferrin, an iron-binding glycoprotein secreted from
glandular epithelial cells, has focused on its role in promoting cuta-
neouswoundhealing by enhancing the initial inﬂammatory phase,
and cell proliferation and migration. Takayama and Aoki (2012)
found using an in vitro model of wound contraction, lactoferrin
promoted ﬁbroblast-mediated collagen gel contraction.
IN VIVO STUDIES – THE EFFECT OF IRON CHELATORS ON CUTANEOUS
WOUND HEALING
There is considerable variability in iron chelator structure,mecha-
nismof action and their consequent applications. Themost widely
used iron chelator used to treat iron over-load is deferoxamine, see
Table 1. Different iron chelators have been applied in studies using
a variety of wound healing models.
Early studies of porcine ﬂap necrosis found that intramuscular
injection of deferoxamine decreased the percentage of ﬂap necro-
sis (Weinstein et al., 1989). This study provided some indirect
evidence suggesting that iron chelators have a positive effect on
woundhealing.Mohammadpour et al. (2013) carried out awound
healing study in Wistar rats, primarily assessing macroscopic
wound area calculations at days 4, 8, and 12. They found that topi-
cal deferiprone treatment accelerated macroscopic wound healing
more than Kojic acid, and on the basis of further DPPH scaveng-
ing assay suggested that this was due to its higher antioxidant and
iron chelation abilities.
Iron chelation results in increased VEGF and HIF 1-α and
positive effect on angiogenesis The effect of iron chelation on
granulation tissue formation and angiogenesis has not been
demonstrated in cutaneous wound healing studies, although there
have been some studies of bone tissue in the context of frac-
ture healing (Phelps et al., 1986; Farberg et al., 2012; Donneys
et al., 2013). Localized Deferoxamine injection has been shown
to both reverse radiation induced hypovascularity and augment
vascularity in pathologic fracture healing.
The incorporation of iron chelators in novel wound dressing
for human chronic wound treatment has also been described.
Wenk et al. (2001) suggested that in human chronic wounds,
wound ﬂuid iron-levels are elevated compared with acute wounds.
They developed a novel wound dressing based on deferoxam-
ine coupled cellulose and in vitro assays suggested that this
dressing may target iron-driven induction of matrix-degrading
metalloproteinase-1 and lipid peroxidation. Taylor et al. (2005)
also developed and described successful biomechanical testing of
deferoxamine coupled polyurethane net substrates.
CLINICAL STUDIES – ROLE OF IRON IN HUMAN CUTANEOUS WOUND
HEALING
Human studies in patients with anemia have focused on wound
strength. These studies have involved small case-series of patients
with a variety of acute surgical conditions. Jonsson et al.
(1991) performed a study of 33 patients undergoing subcu-
taneous implantation of ePTFE graft, collagen deposition was
directly proportional to wound oxygen tension and measures
of perfusion, although the anemia seen in these patients was
not fully described. Pavlidis et al. (2001) carried out a retro-
spective analysis of 89 patients and found that anemia was
not associated with laparotomy wound dehiscence. In a study
of 35 normovolaemic anemic patients undergoing skin graft-
ing, Agarwal et al. (2003) found there was no difference in
wound healing as assessed by mean split-thickness skin graft
take.
To date, human studies have not demonstrated the speciﬁc
effects of iron deﬁciency and anemia on the histological stages of
chronic wound healing. Clinical studies by our group have found
an association betweendiabetic foot ulceration (DFU) severity and
hemoglobin (Hb) decline. DFU is a complex condition, charac-
terized by poor wound healing. Over half all severe DFU patients
have IDA (Khanbhai et al., 2012). Clinically the anemia is difﬁ-
cult to characterize; a signiﬁcant proportion of patients have a
functional iron deﬁciency (FID) caused by chronic inﬂammation
and disruption of the normal Hepcidin mediated iron absorption
pathways.
DYSREGULATION OF LOCAL CUTANEOUS IRON
HOMEOSTASIS IN CHRONIC LEG ULCERATION
Chronic inﬂammatory conditions such as rheumatoid arthritis
(RA) and Lupus Erythematosus are associated with dysregulation
of local cutaneous iron hemostasis.
RA is a progressive inﬂammatory autoimmune disease, with
joint articular and systemic effects including development of
ulceration and poor wound healing. The release of cytokines,
especially TNF-α, IL-6, and IL-1, causes synovial inﬂammation.
Pro-inﬂammatory cytokines also promote the development of sys-
temic effects, including production of acute-phase proteins (such
as CRP) which in turn may contribute to development dysregula-
tion of iron homeostasis and anemia (Choy, 2012). Indeed, clinical
studies of RA patients have reported both iron deﬁciency anemia
and anemia of chronic disease (Bari et al., 2013). Inﬂammation
upregulates the expression of iron-related proteins in the duo-
denum and monocytes of RA patients (Sukumaran et al., 2013).
Evidence for a role for IL-6 signaling in RA is emerging. Isaacs
et al. (2013) found that tocilizumab results in an improvement
in anemia, reduction in hepcidin/haptoglobin and increase in
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Table 1 | Summary of iron chelators.
Iron Chelator Summary
Structure Derivative Mechanisms Application
Deferoxamine
N’ -{5 [Acetyl(hydroxy)amino]
pentyl}-N -[5-({4-[(5-
aminopentyl)
(hydroxy)amino]-4-
oxobutanoyl}amino)pentyl]-
N -hydroxysuccinamide
Hexidentate structure
comprising multiple carbonyl
and hydroxyl groups that donate
electrons Fe3+, making it
chemically inert, by preventing
further redox cycling. Chelates
iron in a one-to-one ratio
Bacterial siderophore
produced by
actinobacteria

⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
Varying rates of
interaction with cellular
iron pools in different
tissues; effects on
plasma iron pools remain
incompletely understood
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐
⏐

Clinically, the most widely used
iron chelator to treat iron
over-load. Applied topically to the
skin in experimental studies
Kojic Acid
5-Hydroxy-2-
(hydroxymethyl)-4H-pyran-4-
one
Bidentate iron chelator Various species of
Aspergillus and
Penicillium in an
anaerobic process
Current applications are
cosmetic: “natural” antioxidant
and skin lightener
Deferiprone
3-hydroxy-1,2-
dimethylpyridin-4(1H )-one
Bidentate iron chelator Antibacterial effect Clinically used for
beta-thalassemia major
treatment; its use is limited by
toxicity (agranulocytosis/ liver
failure). Applied topically to the
skin in experimental studies.
Ciclopiroxolamine
6-cyclohexyl-1-hydroxy-4-
methylpyridin-2(1H )-one
Lipophilic bidentate iron
chelator. Causes loss of function
of catalase and peroxidase
enzymes
Also classiﬁed as a
hydroxypyridinone
antifungal agent.
Further
anti-inﬂammatory
properties
Topical treatment of
onychomycosis, tinea pedis and
corporis.
As can be seen, iron chelators may have antibacterial/antifungal, anti-inﬂammatory and skin lightening effects (Porter, 2009). These mixed effects limit the testing of
experimental hypothesis surrounding role of iron and iron deﬁciency in cutaneous wound-healing.
iron-binding capacity. Approximately 10% of patients with RA
develop leg ulceration.
Clinically, RA leg ulcers are typically associated with venous
insufﬁciency, trauma, arterial insufﬁciency and rarely vasculi-
tis (for review, see Rayner et al., 2009). Further work is needed
to look at the effect of IAD in patients with RA and leg
ulceration.
Lupus Erythematosus is an autoimmune disorder with diverse
clinical manifestation ranging from mild cutaneous disorder
to a life-threatening systemic illness (SLE). Some patients suf-
fer from a skin-limited form (with a variety of manifestations
including oral ulceration), while in others it evolves into SLE,
although this process is not fully understood. A key exogenous
trigger to the onset of cutaneous disease activity is exposure to
UV radiation. It has been shown that photosensitive patients
with cutaneous lesions express anti-Ro/SSA autoantibodies. In
vivo studies have demonstrated up-regulation of antigens such
as Ro52 in keratinocytes (Oke and Wahren-Herlenius, 2013).
This is of some interest; it is possible that iron release in
response to UV radiation impairs the function of these antigens,
which appear to play a role in negative feedback in response to
inﬂammation.
DELETERIOUS EFFECTS OF LOCAL CUTANEOUS IRON
DEPOSITION
There has been some interest in the role of excess iron stored in
the skin as hemosiderin, in the pathophysiology of chronic venous
disease (CVD). It is now thought that the severe skin changes (such
as lipodermatosclerosis) and leg ulceration associated with CVD
happen after iron overload occurs. The mechanisms underlying
the deleterious effects of local cutaneous iron deposition in CVD
are shown in Figure 4.
Recent studies by Sindrilaru et al. (2011) and Sindrilaru (2013)
have identiﬁed a subset of iron-overloaded inﬂammatory M1-
like macrophages, which are implicated in the pathogenesis of
CVD. Hb release from extravasated erythrocytes results in a serum
haptoglobin/hemoglobin complex that is then taken up by the
macrophages, upon upregulation of the hemoglobin–haptoglobin
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FIGURE 4 | Mechanisms of the deleterious effects of local cutaneous
iron deposition in CVD. Venous hypertension (characterized by
abnormally leaky venous valve) leads to extravasation of erythrocytes
with iron. There is increased hemosiderin deposition in the dermis.
Macrophages become loaded with iron (by erythrophagocytosis)
resulting in unrestrained pro-inﬂammatory macrophage activation. ROS
produced cause a cascade of deleterious reactions and increase
oxidative stress. There is further inﬂammatory response through tumor
necrosis factor alpha (TNF-α) and interleukin-6 (IL -6) which is
constantly secreted venous leg ulceration (VLU). Dermal ﬁbrosis is the
result of matrix metalloproteinase (MMP) activation and ﬁbroblast
senescence.
receptor CD163. In CD163high macrophages, continuous uptake
of Hb is thought to be the cause high intracellular concentrations
of heme-iron which induce an unrestrained pro-inﬂammatory
macrophage activation. Macrophage iron can be further increased
during inﬂammation by virtue of increased systemic or local hep-
cidin expression, which leads to reduction in ferroportin, an
iron efﬂux protein, resulting in intracellular iron accumulation.
Individuals may also be predisposed to CVD disease through a
genetic inability to counteract the skin iron overload (Caggiati
et al., 2010). Studies have shown that common hemochromatosis
gene mutations such as the C282Y mutation signiﬁcantly increase
the risk of ulcer in CVD by almost seven times (Zamboni et al.,
2005).
In hereditary hemochromatosis, plasma iron content increases
beyond the iron binding capacity of transferrin, although nor-
mal erythropoiesis is occurring. Studies using quantitative nuclear
microscopy measurements of iron concentration in the epider-
mis (which is a readily accessible tissue) have shown that skin
iron levels reﬂect the liver iron overload. Interestingly, this tech-
nique has been proposed as a clinical tool to enable better
informed decisions on when to initiate, change or stop phle-
botomy therapy. In both CVD and hereditary hemochromatosis,
parenchymal iron deposition leads to activation of metallopro-
teinases and subsequently ﬁbrosis. Hereditary hemochromotosis
has also been used to study the effects of iron on the aging
process. Relative iron overload may also have a deleterious
effect on normal skin aging, as iron chelators assist “suc-
cessful” normal skin aging when applied topically (Polla et al.,
2003).
Leg ulceration represents one of the main causes of morbidity
in sickle cell anemia (SCA). Known risk factors for leg ulcer devel-
opment in SCA include Hb (≤6 g/dL), lower levels of fetal Hb,
hemolysis, raised lactate dehydrogenase (Lobe et al., 1992), infec-
tions and inﬂammation (Cumming et al., 2008). It is likely that in
SCAandother disorders causing hemolytic anemia (such as hered-
itary spherocytosis, thalassemias, and other hemoglobinopathies)
the deleterious effects of excessive local cutaneous or macrophage
iron deposition play key roles in poor wound healing.
CONCLUSION
Over recent years there has been some advancement in knowl-
edge about iron in the skin and iron deﬁciency in cutaneous
wound healing. It is clear from studies on pathology of CVD
that high iron in macrophages can induce unrestrained proin-
ﬂammatory macrophage activation. Furthermore in cases of iron
deﬁciency/anemia of inﬂammation, when serum hepcidin lev-
els are elevated, hepcidin/ferroportin interaction can lead to
increased iron concentration in cells particularly macrophage and
this could also have a detrimental effect on wound healing. Iron
deﬁciency without inﬂammation is likely to affect one of the
later stages of wound healing such as remodeling. Additional
in-depth scientiﬁc study of both the underlying pathophysiolog-
ical mechanisms and role of local cutaneous iron in conditions
associated with iron overload and iron deﬁciency is a priority.
Iron is a potential therapeutic target in the skin by application
of topical iron chelators and other novel pharmacological agents,
and in delayed cutaneous wound healing by treatment of iron
deﬁciency.
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